Key Points
- Insider sale: Solomon Moshkevich sold 3,000 Natera shares on April 1 at an average of $202.30 under a pre-arranged Rule 10b5-1 plan, cutting his stake by about 1.99% to 147,882 shares; this sale continues a series of recent insider dispositions including a 23,205-share sale on Jan. 20.
- Quarterly results: Natera reported a surprising EPS beat ($0.35 vs. consensus -$0.46) and revenue of $665.5M (vs. $600.7M est.), yet the company remains unprofitable with negative ROE and net margin and is forecast to post negative EPS for the year.
- Market and sentiment: Natera has a market cap of about $29.5B and a 12-month range of $125.38–$256.36, with analysts averaging a "Moderate Buy" rating and a $253.47 price target, while institutional investors own roughly 99.9% of the stock and several large funds recently increased positions.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $202.30, for a total value of $606,900.00. Following the transaction, the insider directly owned 147,882 shares in the company, valued at approximately $29,916,528.60. This represents a 1.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Solomon Moshkevich also recently made the following trade(s):
- On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $186,778.95.
- On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $199.85, for a total value of $599,550.00.
- On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The stock was sold at an average price of $230.77, for a total value of $378,232.03.
- On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total transaction of $694,320.00.
- On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total transaction of $285,192.00.
- On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $243,656.89.
- On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $68,855.00.
- On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.
Natera Stock Performance
NASDAQ:NTRA opened at $207.98 on Friday. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36. The firm has a fifty day simple moving average of $207.26 and a 200-day simple moving average of $209.16. The company has a market capitalization of $29.48 billion, a P/E ratio of -135.93 and a beta of 1.68.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The business had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same period in the prior year, the company earned ($0.41) earnings per share. Equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.
Wall Street Analysts Forecast Growth
NTRA has been the subject of several recent analyst reports. TD Cowen restated a "buy" rating on shares of Natera in a research note on Wednesday, January 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Natera in a research report on Thursday, January 22nd. Citigroup initiated coverage on Natera in a report on Wednesday, January 7th. They issued a "buy" rating and a $300.00 price objective on the stock. Zacks Research raised Natera from a "strong sell" rating to a "hold" rating in a research note on Thursday, January 1st. Finally, Wells Fargo & Company increased their target price on Natera from $205.00 to $215.00 and gave the company an "equal weight" rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Natera currently has an average rating of "Moderate Buy" and an average price target of $253.47.
View Our Latest Analysis on NTRA
Hedge Funds Weigh In On Natera
A number of institutional investors have recently added to or reduced their stakes in NTRA. JPMorgan Chase & Co. increased its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP raised its stake in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. State Street Corp raised its stake in Natera by 2.2% during the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock worth $545,624,000 after purchasing an additional 72,087 shares during the period. Franklin Resources Inc. boosted its holdings in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company's stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Finally, Coatue Management LLC grew its stake in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after buying an additional 2,463,008 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
